



SUVEN PHARMACEUTICALS LTD

Regd. Off: 3rd Floor, SDE Serene Chambers, Road No. 5, Banjara Hills, Hyderabad - 500 034


STATEMENT OF UNAUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2023

Rs.in Lakhs

PART - I		STANDALONE					
Sl. No.	PARTICULARS	For the Quarter Ended			For 6 Months Ended		For the Year Ended
		30-09-2023	30-06-2023	30-09-2022	30-09-2023	30-09-2022	31-03-2023
		UN-AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	AUDITED
1	Income						
	Revenue from operations	22,462.13	34,402.56	27,840.18	56,864.69	61,720.09	1,33,007.98
	Other Income	1,420.02	1,005.90	1,038.94	2,425.92	2,128.69	4,455.20
	Total income	23,882.15	35,408.46	28,879.12	59,290.61	63,848.78	1,37,463.18
2	Expenses						
	a) Cost of materials consumed	4,694.69	7,762.36	8,433.67	12,457.05	19,663.07	42,136.24
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	897.29	2,149.98	33.02	3,047.27	(1,531.11)	(2,094.42)
	c) Manufacturing Expenses	2,778.51	3,110.31	4,449.52	5,888.82	8,588.21	17,087.35
	d) Employee benefits expense	2,651.34	2,627.01	2,588.69	5,278.35	5,067.95	10,084.31
	e) R & D expense	447.39	208.80	207.46	656.19	430.69	858.57
	f) Finance costs	50.28	114.65	29.03	164.93	172.28	539.17
	g) Depreciation and amortisation expenses	1,048.10	1,114.77	1,075.57	2,162.87	2,130.35	4,284.46
	h) Other Expenses	1,257.52	1,555.91	1,463.55	2,813.43	3,363.04	6,628.17
	Total expenses	13,825.12	18,643.79	18,280.51	32,468.91	37,884.48	79,523.85
3	Profit before exceptional items & Tax (1-2)	10,057.03	16,764.67	10,598.61	26,821.70	25,964.30	57,939.33
4	Exceptional Items	-	-	-	-	-	-
5	Profit before Tax (3-4)	10,057.03	16,764.67	10,598.61	26,821.70	25,964.30	57,939.33
6	Tax Expenses						
	a) Current tax	2,429.26	4,131.07	2,562.47	6,560.33	6,450.57	14,462.56
	b) Deferred tax	155.16	204.25	143.86	359.41	216.28	433.75
	c) Prior year tax	-	-	-	-	-	(217.23)
7	Net Profit/ (Loss) for the period/year(5-6)	7,472.61	12,429.35	7,892.28	19,901.96	19,297.45	43,260.25
8	Other Comprehensive Income						
8.a	(i) Items that will not be reclassified to profit or loss	-	1.21	(25.49)	1.21	(50.97)	(35.16)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	(0.30)	6.42	(0.30)	12.83	8.85
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive Income	-	0.91	(19.07)	0.91	(38.14)	(26.31)
9	Total Comprehensive Income for the period (7+8)	7,472.61	12,430.26	7,873.21	19,902.87	19,259.31	43,233.94
10	Paid-up equity share capital Face Value of the Share	2,545.65 Re.1.00	2,545.65 Re.1.00	2,545.65 Re.1.00	2,545.65 Re.1.00	2,545.65 Re.1.00	2,545.65 Re.1.00
11	Other Equity						1,72,392.41
12	Earning Per Share (EPS)-Face value of Rs.1/- each)						
	a) Basic	2.94	4.88	3.10	7.82	7.58	16.99
	b) Diluted	2.94	4.88	3.10	7.82	7.58	16.99
		(not annualised)	(annualised)				



PART - II		CONSOLIDATED					
Sl. No.	PARTICULARS	For the Quarter Ended			For 6 Months Ended		For the Year Ended
		30-09-2023	30-06-2023	30-09-2022	30-09-2023	30-09-2022	31-03-2023
		UN-AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	AUDITED
1	Income						
	Revenue from operations	23,105.37	34,755.01	27,840.18	57,860.38	61,720.09	1,34,032.88
	Other Income	1,984.17	1,066.51	1,092.00	3,050.68	2,195.31	4,636.38
	Total income	25,089.54	35,821.52	28,932.18	60,911.06	63,915.40	1,38,669.26
2	Expenses						
	a) Cost of materials consumed	5,115.60	7,977.18	8,575.01	13,092.78	19,848.56	43,007.88
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	644.73	2,149.98	21.93	2,794.71	(1,542.20)	(2,094.42)
	c) Manufacturing Expenses	2,927.86	3,227.53	4,614.82	6,155.39	8,845.77	17,628.79
	d) Employee benefits expense	2,857.68	2,874.40	2,864.78	5,732.08	5,523.34	11,051.09
	e) R & D expense	447.39	208.80	207.46	656.19	430.69	858.57
	f) Finance costs	50.28	114.65	29.34	164.93	174.50	543.63
	g) Depreciation and amortisation expense	1,189.19	1,254.12	1,203.05	2,443.31	2,353.51	4,773.24
	h) Other Expenses	1,315.98	1,620.55	1,568.24	2,936.53	3,537.77	6,927.50
	Total expenses	14,548.71	19,427.21	19,084.63	33,975.92	39,171.94	82,696.28
3	Profit before exceptional items , Tax & share in profit/(Loss) of Associates (1-2)	10,540.83	16,394.31	9,847.55	26,935.14	24,743.46	55,972.98
4	Add : Share of profit/(Loss) of Associates.	-	-	-	-	-	-
5	Profit before exceptional items , Tax (3+4)	10,540.83	16,394.31	9,847.55	26,935.14	24,743.46	55,972.98
6	Exceptional Items	-	-	-	-	-	-
7	Profit before Tax (5-6)	10,540.83	16,394.31	9,847.55	26,935.14	24,743.46	55,972.98
8	Tax Expenses						
	a) Current tax	2,429.26	4,131.07	2,498.06	6,560.33	6,567.34	14,627.43
	b) Deferred tax	155.16	204.25	143.86	359.41	216.28	433.75
	c) Prior year tax	-	-	-	-	-	(217.23)
9	Net Profit/ (Loss) for the period/year(7-8)	7,956.41	12,058.99	7,205.63	20,015.40	17,959.84	41,129.03
10	Other Comprehensive Income						
10.a	(i) Items that will not be reclassified to profit or loss	-	1.21	(25.60)	1.21	(51.17)	(27.49)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	(0.30)	6.42	(0.30)	12.83	8.85
10.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive Income	-	0.91	(19.18)	0.91	(38.34)	(18.64)
11	Total Comprehensive Income for the period (9 + 10)	7,956.41	12,059.90	7,186.45	20,016.31	17,921.50	41,110.39
12	Paid-up equity share capital Face Value of the Share	2,545.65 Re.1.00	2,545.65 Re.1.00	2,545.65 Re.1.00	2,545.65 Re.1.00	2,545.65 Re.1.00	2,545.65 Re.1.00
13	Other Equity						1,70,972.78
14	Earning Per Share (EPS)- (Face value of Rs.1/- each)						
	a) Basic -	3.13	4.74	2.83	7.86	7.06	16.16
	b) Diluted	3.13	4.74	2.83	7.86	7.06	16.16
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)



- Notes**
- 1) The above financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 9th November, 2023. The results for the for the quarter ended 30th September , 2023 has been reviewed by our statutory auditors.
 - 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
 - 3) The consolidated financial results include the results of the wholly owned subsidiaries Suven Pharma, Inc.,USA & Casper Pharma Pvt Ltd.
 - 4) The Company reportable activity falls under single business segment and hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.
 - 5) As per share purchase agreement dated 26th December, 2022 entered into by and between Berhyanda Limited (Buyer), Jasti Property and Equity Holdings Private Limited (in their capacity as sole trustee of Jasti Family Trust) (Seller) and Venkateswarlu Jasti (seller representative) pursuant to SEBI SAST Regulations, 2011 as amended, M/s Berhyanda Limited, a Cyprus based company and an investment arm of Advent International Corporation, USA has acquired controlling stake to the tune of 12,75,37,043 equity shares aggregating to 50.10 % in the Company on 29th September, 2023 from the Seller.
 - 6) The corresponding previous period figures have been regrouped/reclassified where ever necessary.



For SUVEN PHARMACEUTICALS LTD

[Handwritten Signature]

Dr. V. PRASADA RAJU

Managing Director

DIN: 07267366

Place : Hyderabad


Date : 09th November ' 2023

Statement of Assets & Liabilities

Rs.in Lakhs

Particulars	Standalone as at		Consolidated as at	
	30-09-2023	31-03-2023	30-09-2023	31-03-2023
	Un-Audited	Audited	Un-Audited	Audited
A ASSETS				
1 Non-current assets				
(a) Property, Plant and Equipment	49,898.76	50,900.87	57,167.11	58,418.83
(b) Capital Work-in-Progress	17,192.46	16,481.46	17,232.71	16,508.86
(c) Other Intangible Assets	176.28	193.20	6,202.11	6,219.02
(e) Right of use of assets	156.22	108.67	1,724.73	1,694.80
(f) Financial Assets				
I. Investments	31,721.01	31,721.01	11,709.66	11,709.66
II. Loans	2.72	2.25	2.72	2.25
III. Other Financial Assets	679.70	591.19	681.83	591.19
(g) Other non current assets	349.55	322.75	349.60	325.19
Total Non-Current assets	1,00,176.70	1,00,321.40	95,070.47	95,469.80
2 Current assets				
(a) Inventories	26,401.76	31,146.62	27,146.29	31,281.05
(b) Financial Assets				
I. Investments	63,594.17	39,284.94	65,287.58	41,893.50
II. Trade Receivables	13,341.80	10,966.45	13,689.87	11,093.93
III. Cash and Cash equivalents	2,675.38	4,302.13	5,757.67	6,480.28
IV. Bank balances otherthan (III) above	322.92	321.13	322.92	321.12
V. Loans	26.57	19.29	26.57	19.29
VI. Other financial Assets	15.50	28.17	15.50	28.17
(d) Other current assets	4,393.57	9,442.91	4,660.47	9,987.24
Total Current assets	1,10,771.67	95,511.64	1,16,906.87	1,01,104.58
TOTAL - ASSETS	2,10,948.37	1,95,833.04	2,11,977.34	1,96,574.38
B EQUITY AND LIABILITIES				
1 EQUITY				
(a) Equity Share Capital	2,545.65	2,545.65	2,545.65	2,545.65
(b) Other Equity	1,92,295.29	1,72,392.41	1,90,994.73	1,70,972.78
Equity attributable to owners of the company	1,94,840.94	1,74,938.06	1,93,540.38	1,73,518.43
2 LIABILITIES				
(a) Financial Liabilities				
I. Lease Liability	86.78	69.98	86.78	69.98
II. Borrowings	-	456.42	-	456.42
(b) Provisions	866.52	786.52	921.72	829.51
(c) Deferred tax Liabilities (net)	4,524.16	4,164.45	6,190.61	5,823.46
Total non-current liabilities	5,477.46	5,477.37	7,199.11	7,179.37
Current liabilities				
(a) Financial Liabilities				
I. Lease Liability	78.60	47.90	78.59	47.90
II. Borrowings	4,913.31	6,459.78	4,913.31	6,459.78
III. Trade payables				
a) To Micro & Small Enterprises	708.15	1,382.03	707.81	1,383.01
b) Other than Micro & Small Enterprises	2,982.22	4,814.35	3,551.58	5,133.42
IV. Other Financial Liabilities	928.53	2,015.35	946.22	2,133.20
(b) Current Tax liabilities (Net)	43.76	30.41	39.85	29.39
(c) Provisions	505.68	385.68	509.68	394.61
(d) Other Current liabilities	469.72	282.11	490.81	295.27
Total Liabilities	10,629.97	15,417.61	11,237.85	15,876.58
Total Liabilities	16,107.43	20,894.98	18,436.96	23,055.95
TOTAL - EQUITY AND LIABILITIES	2,10,948.37	1,95,833.04	2,11,977.34	1,96,574.38

For Suvan pharmaceuticals Ltd



Dr. V. PRASADA RAJU
Managing Director
DIN: 07267366

 Place : Hyderabad
Date : 09th November '2023


SUVEN PHARMACEUTICALS LIMITED
STANDALONE STATEMENT OF CASH FLOWS

(All amounts in lakhs, unless otherwise stated)

Particulars	For the period ended Sept 30, 2023	For the period ended Sept 30, 2022
A. Cash flow from operating activities		
Profit/(Loss) before tax	26,821.70	25,964.30
Adjustments :		
Depreciation and amortisation expense	2,129.94	2,085.09
Interest income	(105.75)	(283.70)
Finance costs	164.93	172.28
Gain on sale of current investment	(1,728.33)	(585.93)
Dividend received from subsidiaries	-	-
Debit balances written off	-	-
Effects of foreign exchange rates (unrealized)	68.65	46.82
Loss/(Profit) on disposal of property, plant & equipment	2.59	0.65
Operating profit before working capital changes	27,353.73	27,399.51
Adjustments for (Increase)/decrease in operating assets		
Trade receivables	(2,407.68)	12,474.95
Inventories	4,744.87	(3,376.12)
Other non current assets	(47.55)	57.91
Other current assets	5,048.89	17.83
Adjustments for Increase/(decrease) in operating liabilities		
Trade payables	(2,506.18)	(2,163.17)
Long term provisions	80.00	-
Short term provision	121.21	299.03
Other financial liabilities	(364.35)	(280.14)
Other current liabilities	187.85	1,177.23
Cash generated from operating activities	32,210.79	35,607.04
Income taxes paid (net of refunds)	(6,546.98)	(5,484.18)
Net Cash flows from operating activities	(A) 25,663.81	30,122.86
B. Cash flow from investing activities		
Purchase of property, plant and equipment	(2,570.88)	(5,951.65)
Proceeds from sale of property, plant & equipment	-	7.20
Investment in subsidiaries	-	(19,853.72)
Dividend received from subsidiaries	-	-
Interest received from FD and debentures	105.75	-
Fixed deposits/margin money-placed/matured	(75.63)	(57.79)
Sale/(purchase) of mutual funds	(22,580.91)	19,473.16
Bank balances not considered as cash and cash equivalents	(4.68)	(1,548.13)
Net cash flow from / (used in) investing activities	(B) (25,126.35)	(7,930.93)
C. Cash flows from financing activities		
(Repayment)/proceeds from long term borrowings	(456.89)	(824.18)
(Repayment)/proceeds from short term borrowings	(1,589.89)	323.55
Repayment of lease liabilities	47.49	(64.13)
Finance costs paid	(164.93)	(172.28)
Other non current financial assets	-	5.00
Other current financial assets	-	2.25
Interest received	-	283.70
Dividends paid to equity holders	-	(20,365.20)
Net cash flow from / (used in) financing activities	(C) (2,164.21)	(20,811.28)
Net increase/(decrease) in cash and cash equivalents	(A+B+C) (1,626.75)	1,380.65
Cash and cash equivalents as at the beginning of the year	4,302.13	3,021.05
Effect of exchange differences on restatement on foreign currency cash & cash equivalents	-	-
Cash and cash equivalents at the end of the year	2,675.38	4,401.70
Cash and cash equivalents	2,675.38	4,401.70
Balances per statement of cash flows	2,675.38	4,401.70

This is the Cash Flow Statement referred to in our report of even date

Note 1 -The above statement of cash flow has been prepared under the 'Indirect Method' as set out in the Indian Accounting Standard 7 (Ind AS-7) "Statement of Cash Flows"

For Suven pharmaceuticals Ltd

Dr. V. PRASADA RAJU
Managing Director
DIN: 07267366



Place : Hyderabad
Date : 09th November '2023

SUVEN PHARMACEUTICALS LIMITED
CONSOLIDATED STATEMENT OF CASH FLOWS

(All amounts in lakhs, unless otherwise stated)

Particulars	For the period ended Sept 30, 2023	For the period ended Sept 30, 2022
A. Cash flow from operating activities		
Profit before tax	26,935.14	24,743.46
Adjustments :		
Depreciation and amortisation expense	2,410.38	2,292.63
Interest income	(635.39)	(294.40)
Finance costs	164.93	174.50
Gain on sale of current Investment	(1,728.33)	(639.54)
Dividend received from subsidiaries	-	-
Debit balances written off	-	-
Effects of foreign exchange rates (unrealized)	68.65	46.82
Loss/(Profit) on disposal of property, plant & equipment	2.59	0.65
Operating profit before working capital changes	27,217.97	26,324.12
Adjustments for (Increase)/decrease in operating assets		
Trade receivables	(2,628.27)	12,474.95
Inventories	4,134.76	(3,489.07)
Other non current assets	(47.55)	(1,545.79)
Other current assets	5,326.77	(114.07)
Adjustments for Increase/(decrease) in operating liabilities		
Trade payables	(2,257.21)	(2,034.46)
Long term provisions	92.22	51.47
Short term provision	115.07	301.24
Other financial liabilities	(370.67)	(340.59)
Other current liabilities	195.54	1,194.15
Cash generated from operating activities	31,778.61	32,821.95
Income taxes paid (net of refunds)	(6,548.01)	(5,682.26)
Net Cash flows from operating activities (Refer Note 1)	(A) 25,230.60	27,139.69
B. Cash flow from Investing activities		
Purchase of property, plant and equipment	(2,681.84)	(19,374.76)
Proceeds from sale of property, plant & equipment	-	7.20
Interest received from FD and debentures	710.24	-
Foreign currency translation reserve	5.64	75.23
Fixed deposits/margin money-placed/matured	(77.76)	672.59
Sale/(purchase) of mutual funds	(21,740.60)	16,031.62
Bank balances not considered as cash and cash equivalents	(4.68)	(1,548.13)
Net cash flow from /(used in) investing activities	(B) (23,789.00)	(4,136.25)
C. Cash flows from financing activities		
(Repayment)/proceeds from long term borrowings	(456.89)	(824.18)
(Repayment)/proceeds from short term borrowings	(1,589.89)	323.55
Repayment of lease liabilities	47.49	(64.13)
Finance costs paid	(164.93)	(174.50)
Other non current financial assets	-	5.00
Other current financial assets	-	2.25
Interest received	-	294.40
Dividends paid to equity holders	-	(20,365.20)
Net cash flow from /(used In) financing activities	(C) (2,164.21)	(20,802.81)
Net increase/(decrease) in cash and cash equivalents	(A+B+C) (722.60)	2,200.63
Cash and cash equivalents as at the beginning of the year	6,480.28	4,456.38
Effect of exchange differences on restatement on foreign currency cash & cash equivalents	-	-
Cash and cash equivalents at the end of the year	5,757.67	6,657.01
Cash and cash equivalents	5,757.67	6,657.01
Balances per statement of cash flows	5,757.67	6,657.01

This is the Cash Flow Statement referred to in our report of even date

Note 1 -The above statement of cash flow has been prepared under the 'Indirect Method' as set out in the Indian Accounting Standard 7 (Ind AS-7) "Statement of Cash Flows"

Place : Hyderabad

Date : 09th November '2023

For Suvan pharmaceuticals Ltd

Dr. V. PRASADA RAJU

Managing Director

DIN: 07267366

